RESEARCH REPORT Leah Lawrence Women diagnosed with endometrial cancer at age 50 or younger had a fourfold increased risk for a subsequent colorectal cancer diagnosis, according to a historical cohort study published recently in the Journal of Clinical Oncology.
REVIEW ARTICLE Francesco Cellini, Vincenzo Valentini;ONCOLOGY Vol. 26 No. 8 The preferred integrated treatment modality for locally advanced rectal cancer is preoperative radio(chemo)therapy followed by total mesorectal excision, though certain aspects of this standard are still debated.
Patients who have chronic constipation may be at increased risk for colorectal cancer and benign neoplasms, researchers reported at the American College of Gastroenterology 77th Annual Scientific Meeting. In addition, new colonoscopy surveillance... More »
CT colonography is a better screening test than optical colonoscopy (OC), according to a new study published in the May Radiology print issue. Using meta-analysis of studies done over a 15 year period, authors found that the sensitivity of CT... More »
Statins are associated with a slight reduction in the risk of colorectal cancer, according to the results of a recent meta-analysis presented at the 2010 American College of Gastroenterology meeting. Investigators at the University of Michigan at Ann... More »
Adult stem cells are present in most postnatal tissues of mammals. Tissues with high rates of cell turnover depend on the functional capacity of stem cells for lifelong maintenance of tissue homeostasis. Adult stem cells are also required for the regeneration of tissues in response to injury as in, for example, the regeneration of skeletal muscle. In addition to its function in tissue homeostasis and regeneration, adult stem cells can represent the cell type of origin of various types of cancers including
Although experimental studies have shown lipoprotein(a) antiangiogenic and antitumoral effects, the association of lipoprotein(a) levels with cancer in population studies remains elusive and poorly documented. The aim of this study was to analy
Decision making for adjuvant chemotherapy in stage III colon cancer is based on the TNM system. It is well known that prognosis worsens with higher pN classification, and several recent studies propose superiority of the lymph node ratio (ln ratio) to the TNM system. Therefore, we compared the prognosis of ln ratio to TNM system in our stage III colon cancer patients.|Decision making for adjuvant chemotherapy in stage III colon cancer is based on the TNM system. It is well known that prognosis worsens with
The active form of vitamin D3, 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), is mostly known for its importance in the maintenance of calcium and phosphate homeostasis. However, next to its classical effects on bone, kidney and intestine, 1,25(OH)2D3 also exerts antineoplastic effects on various types of cancer. The use of 1,25(OH)2D3 itself as treatment against neoplasia is hampered by its calcemic side effects. Therefo
FAM3B mRNA has been predicted to have multiple splicing forms. Its secretory form PANDER is decreased in gastric cancers with high invasiveness and metastasis. Here we found that its non-secretory form FAM3B-258 was highly expressed in most colon cancer cell lines and colorectal adenocarcinoma tissues but not hepatocellular carcinoma, lung carcinoma and pancreatic adenocarcinoma cell lines. Elevation of FAM3B-258 was associated with poor cancer cell differentiation. Stable overexpression of FAM3B-258 in colon cancer cells downregulated adhesion proteins, upregulated Slug and Cdc42, promoted cell migration and invasion in vitro and metastasis in nude mice. Slug mediated FAM3B-258-induced downregulation of adhesion molecules, upregulation of Cdc42, and invasion of colon cancer cells. The expression of FAM3B-258 in human colorectal adenocarcinomas was positively correlated with Slug. These results suggest that FAM3B-258 promotes colon cancer cell invasion and metastasis through
No treatment options are available for patients with metastatic colorectalcancer that progresses after all approved standard therapies, but many patients maintain a good performance status and could be candidates for further therapy. An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients.|We did this trial at 114 centres in 16 countries. Patients with documented metastatic colorectalcancer and progression during or within 3 months after the last standard therapy were randomised (in a 2:1 ratio; by computer-generated randomisation list and interactive voice response system; preallocated block design (block size six); stratified by previous treatment with VEGF-targeting drugs, time from diagnosis of metastatic disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 weeks of each 4 week cycle. The primary endpoint was overall survival. The study sponsor,
23323906 2013 01 17 2013 01 23 1533-4406 368 3 Jan 17 N. Engl. J. Med. 282-4 10.1056/NEJMcibr1212341 School of Medicine, Cardiff University, Cardiff, Wales, United Kingdom. Gallimore Awen M AM Godkin Andrew A eng Journal Article United States N Engl
23323915 2013 01 17 2013 01 23 1533-4406 368 3 Jan 17 N. Engl. J. Med. 289 10.1056/NEJMc1214189 SA2 Sahin Ibrahim H IH Garrett Christopher C eng Comment Letter United States N Engl J Med 0255562 0028-4793 0 Cyclooxygenase 2 Inhibitors 0 Tumor Markers